Emil D. Kakkis, President and CEO of Ultragenyx Pharmaceutical Inc. ($RARE), sold $1.24 million worth of shares on the open market once in the last 365 days. His most recent sale occurred on March 2, 2026. This places him 4,439th among 11,678 insiders by total sales value, well below the average of $8.6 million across 6.37 transactions. Kakkis made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | S | Common Stock | 54404 | $22.80 | 2,817,979.0000 | 98,600,000 | 1.89% | 0.06% |
| March 1, 2026 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | A | Common Stock | 71177 | $0.00 | 2,871,893.0000 | 98,600,000 | 2.54% | 0.07% |
| March 3, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | S | Common Stock | 73434 | $42.10 | 2,800,716.0000 | 90,538,118 | 2.55% | 0.08% |
| Feb. 28, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | S | Common Stock | 25000 | $42.48 | 2,800,716.0000 | 90,538,118 | 0.88% | 0.03% |
| March 1, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | A | Stock Option (Right to Buy) | 78448 | $0.00 | 78,448.0000 | 90,538,118 | 9999.99% | 0.09% |
| March 1, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | A | Common Stock | 43268 | $0.00 | 2,766,858.0000 | 90,538,118 | 1.59% | 0.05% |
| March 1, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | A | Common Stock | 107292 | $0.00 | 2,874,150.0000 | 90,538,118 | 3.88% | 0.12% |
| Dec. 30, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | S | Common Stock | 11727 | $42.23 | 2,748,590.0000 | 95,493,996 | 0.42% | 0.01% |
| Dec. 10, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | S | Common Stock | 8273 | $50.00 | 2,760,317.0000 | 95,493,996 | 0.30% | 0.01% |
| Dec. 9, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | G | Common Stock | 20000 | $0.00 | 2,768,590.0000 | 95,493,996 | 0.72% | 0.02% |
| Sept. 3, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | S | Common Stock | 20000 | $55.85 | 2,788,582.0000 | 73,543,862 | 0.71% | 0.03% |
| Aug. 6, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | S | Common Stock | 20000 | $50.17 | 2,808,582.0000 | 73,543,862 | 0.71% | 0.03% |
| March 1, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | A | Common Stock | 3132 | $0.00 | 2,827,898.0000 | 73,543,862 | 0.11% | 0.00% |
| March 1, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | A | Stock Option (Right to Buy) | 70094 | $0.00 | 70,094.0000 | 73,543,862 | 9999.99% | 0.10% |
| March 1, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | A | Common Stock | 38428 | $0.00 | 2,842,183.0000 | 73,543,862 | 1.37% | 0.05% |
| March 1, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | F | Common Stock | 17417 | $53.69 | 2,824,766.0000 | 73,543,862 | 0.61% | 0.02% |
| Feb. 7, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | S | Common Stock | 30000 | $45.00 | 2,803,755.0000 | 73,543,862 | 1.06% | 0.04% |
| Dec. 29, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | S | Common Stock | 30000 | $47.87 | 2,833,755.0000 | 69,914,225 | 1.05% | 0.04% |
| Oct. 19, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | M | Stock Option (Right to Buy) | 47853 | $0.00 | 0.0000 | 69,914,225 | 100.00% | 0.07% |
| Oct. 19, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | M | Common Stock | 47853 | $6.86 | 2,911,014.0000 | 69,914,225 | 1.67% | 0.07% |
| Oct. 19, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | S | Common Stock | 47853 | $33.52 | 2,863,728.0000 | 69,914,225 | 1.64% | 0.07% |
| March 1, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | F | Common Stock | 16140 | $45.65 | 2,863,161.0000 | 69,914,225 | 0.56% | 0.02% |
| March 1, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | A | Stock Option (Right to Buy) | 83500 | $0.00 | 83,500.0000 | 69,914,225 | 9999.99% | 0.12% |
| March 1, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | A | Common Stock | 46200 | $0.00 | 2,879,591.0000 | 69,914,225 | 1.63% | 0.07% |
| March 1, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | A | Common Stock | 8716 | $0.00 | 2,833,391.0000 | 69,914,225 | 0.31% | 0.01% |
| Dec. 30, 2022 | Ultragenyx Pharmaceutical Inc. | $RARE | KAKKIS EMIL D | President & CEO | S | Common Stock | 19582 | $45.57 | 2,824,385.0000 | 0 | 0.69% | 0.00% |